Comparison of Dabigatran Etexilate Self-Micro-Emulsifying Drug Delivery Systems Formulation Optimization Techniques: Design Expert Vs. MATLAB

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Rama Devi Korni, Majji Akhil, Bora Thanmaisree, Jagadeesh Panda, Killana Sre Meghna
{"title":"Comparison of Dabigatran Etexilate Self-Micro-Emulsifying Drug Delivery Systems Formulation Optimization Techniques: Design Expert Vs. MATLAB","authors":"Rama Devi Korni,&nbsp;Majji Akhil,&nbsp;Bora Thanmaisree,&nbsp;Jagadeesh Panda,&nbsp;Killana Sre Meghna","doi":"10.1007/s12247-025-09990-7","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>This work aimed to formulate Dabigatran etexilate, a BCS class II medication, as self-micro-emulsifying drug delivery system (SMEDDS) to increase its rate of dissolution. By doing solubility experiments of the medication in various oils, surfactants, and cosurfactants, the three primary formulation components of a SMEDDS formulation were chosen. Formulation design and optimization were done by Box-Behnken design in Design Expert software. A comparative study was conducted with artificial neural networks (ANN) using MATLAB Software for better prediction of the selected output variables. The formulations were made and tested for transmittance and drug release percentages. The desirability function was used to create an optimal formulation, which was then made and tested for emulsification time, centrifugation, viscosity, cloud point, dilution and phase separation. Neusilin was used as an adsorbent to further solidify the optimized formulation and produce a stable product. The solidified optimized formulation was then subjected to fourier transform infrared spectroscopy and x-ray diffraction studies.</p><h3>Results</h3><p>The optimized SMEDDS Dabigatran etexilate formulations contained mixtures of Kollisolv MCT70 (oil), Kolliphor EL (surfactant), and PEG 400 (cosurfactant). The higher R<sup>2</sup> values and lower MSE values of percentage drug release and percentage transmittance for ANN compared to Box-Behnken design-based quadratic model indicate better predictability of ANN. In vitro release of optimized SMEDDS was 81.09 ± 1.37% within 1 h. It exhibited a significant transmittance of 89 ± 0.63%.</p><h3>Conclusion</h3><p>The results indicated that SMEDDS capsules could be effectively used to improve the solubility rate of Dabigatran etexilate. ANN can be successfully used as a better model for predicting characteristics of formulations.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-09990-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

This work aimed to formulate Dabigatran etexilate, a BCS class II medication, as self-micro-emulsifying drug delivery system (SMEDDS) to increase its rate of dissolution. By doing solubility experiments of the medication in various oils, surfactants, and cosurfactants, the three primary formulation components of a SMEDDS formulation were chosen. Formulation design and optimization were done by Box-Behnken design in Design Expert software. A comparative study was conducted with artificial neural networks (ANN) using MATLAB Software for better prediction of the selected output variables. The formulations were made and tested for transmittance and drug release percentages. The desirability function was used to create an optimal formulation, which was then made and tested for emulsification time, centrifugation, viscosity, cloud point, dilution and phase separation. Neusilin was used as an adsorbent to further solidify the optimized formulation and produce a stable product. The solidified optimized formulation was then subjected to fourier transform infrared spectroscopy and x-ray diffraction studies.

Results

The optimized SMEDDS Dabigatran etexilate formulations contained mixtures of Kollisolv MCT70 (oil), Kolliphor EL (surfactant), and PEG 400 (cosurfactant). The higher R2 values and lower MSE values of percentage drug release and percentage transmittance for ANN compared to Box-Behnken design-based quadratic model indicate better predictability of ANN. In vitro release of optimized SMEDDS was 81.09 ± 1.37% within 1 h. It exhibited a significant transmittance of 89 ± 0.63%.

Conclusion

The results indicated that SMEDDS capsules could be effectively used to improve the solubility rate of Dabigatran etexilate. ANN can be successfully used as a better model for predicting characteristics of formulations.

Graphical Abstract

达比加群酯自微乳化给药系统配方优化技术的比较:设计专家与MATLAB
本研究旨在将BCSⅱ类药物达比加群酯配制成自微乳化给药系统(SMEDDS),以提高其溶出速度。通过对药物在各种油脂、表面活性剂和助表面活性剂中的溶解度实验,选择了SMEDDS配方的三种主要配方成分。在design Expert软件中采用Box-Behnken设计进行配方设计和优化。利用MATLAB软件与人工神经网络(ANN)进行对比研究,以更好地预测所选择的输出变量。制备了该制剂并进行了透光率和释药率的测定。利用期望函数得到最佳配方,并对乳化时间、离心、粘度、浊点、稀释度、相分离进行了测试。以新丝林为吸附剂,进一步固化优化后的配方,得到稳定的产品。然后对固化后的优化配方进行了傅里叶变换红外光谱和x射线衍射研究。结果优选的SMEDDS达比加群酯制剂由Kollisolv MCT70(油)、Kolliphor EL(表面活性剂)和peg400(助表面活性剂)组成。与基于Box-Behnken设计的二次模型相比,人工神经网络药物释放百分比和透过率的R2值较高,MSE值较低,表明人工神经网络的可预测性较好。优化后的SMEDDS在1 h内的体外释放率为81.09±1.37%,透过率为89±0.63%。结论SMEDDS胶囊可有效提高达比加群酯的溶解度。人工神经网络可以成功地作为一个更好的模型来预测配方的特性。图形抽象
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信